Introduction {#S0001}
============

According to GLOBOCAN,[@CIT0001] lung cancer accounted for the majority of global cancer incidence and deaths in 2012. Pathogenic factors for lung cancer include both genetic and environmental factors.[@CIT0002],[@CIT0003] In recent years, the role of infection in the etiology of cancer has gained scientific interest.

Chlamydia pneumoniae (Cpn) is a common cause of acute respiratory infections, and the inflammation caused by chronic infection may lead to carcinogenesis. Epidemiological evidence suggests that Cpn infection may be associated with the development and progression of lung cancer.[@CIT0004] A recent meta-analysis of 2,549 patients with lung cancer and 2,764 controls showed that Cpn infection significantly increased the risk of lung cancer (odds ratio =2.07, 95% confidence interval: 1.43--2.99).[@CIT0005] Cell experiments found that Cpn infection can induce human mesothelial cell transformation, thereby increasing the risk of lung cancer.[@CIT0006] Studies using integrated computer methods found that Cpn triggered lung cancer growth by changing host cell replication, transcription, and DNA damage repair mechanisms[@CIT0007]

The underlying molecular mechanism of Cpn chronic infection-mediated lung cancer is not yet clear. Studies have shown that inflammation-induced lung cancer differs from genetic- and epigenetic-mediated cancer development.[@CIT0008] DNA methylation is an important epigenetic mechanism that regulates gene transcription and cell function.[@CIT0009] It regulates gene expression without changing gene sequences. DNA methylation usually inhibits gene expression, while demethylation induces gene activation and expression. Early carcinogenesis can cause abnormal changes in methylation, and methylation can be detected in bodily fluids and early lesions of biopsied tissues. Methylation can be reversed by demethylating drugs, suggesting that methylation-mediated gene abnormalities may serve as a biological target for early detection of lung cancer and treatment interventions.

To explore the pathogenic effect of Cpn on lung cancer and its underlying epigenetic mechanism, we used the high-throughput Illumina methylation 450 k array to determine the methylation levels of the whole genome in lung cancer tissues and para-cancer controls. We revealed methylation characteristics of serologic Cpn positive lung cancer and found that the combination of methylation and expression profiles identified 62 potentially functional methylated abnormal genes associated with Cpn. Furthermore, we identified the role of abnormal methylation in the development and progression of lung cancer at the molecular level.

Materials and methods {#S0002}
=====================

Subjects {#S0002-S2001}
--------

Twelve newly diagnosed primary lung cancer cases that tested positive for Cpn serological antibodies (IgA and IgG) and 12 cases that were negative following thoracic surgery in the First Affiliated Hospital of Fujian Medical University were selected and matched for demographic characteristics, clinicopathological features, and lifestyles ([Table 1](#T0001){ref-type="table"}). Twelve pairs of patients were tested using methylation and expression microarrays, and methylation levels of the promoter region in the target genes were verified using the Sequenom methylation method (see [Table 1](#T0001){ref-type="table"}, No. 1--6); the remaining twelve pairs were validated using the MethylTarget method (see [Table 1](#T0001){ref-type="table"}, No. 7--12). No patient received adjuvant therapy, such as radiotherapy and chemotherapy, before surgery. Lung cancer tissues and corresponding normal tissues were resected and stored at −80 °C within 10 min after surgery. Histopathological diagnosis of each specimen was performed independently by two pathologists ([Figure 1](#F0001){ref-type="fig"}). The study protocol was approved by the institutional review board of Fujian Medical University, and written informed consent was obtained from all patients. This study was conducted in accordance with the Declaration of Helsinki.Table 1Demographic and clinical characteristics of the lung cancer patientsNo.AgeSexPathological categoryTNM stagingCpn IgA&GA1/B156FADCT4N2M0 Ⅲ b+C1/D156FADCT4N1M0 Ⅲ a−A2/B241FADCT1aN0M0 Ⅱ a+C2/D244FADCT2aN1M0 Ⅱ a−A3/B360MADCT2N0M0 Ⅱ a+C3/D358MADCT2N0M0 Ⅱ b−A4/B460MADCT2aN2M0 Ⅲ a+C4/D459MADCT2N0M0 Ⅰ b−A5/B566MSCCT1aN2M0 Ⅲ a+C5/D567MSCCT2aN0M0 Ⅰ b−A6/B658MSCCT1aN0M0 Ⅰ a+C6/D660MSCCT1aN0M0 Ⅰ a−A7/B759MSCCT2aN1M0 Ⅱa+C7/D757MSCCT1N1M0 Ⅱa−A8/B849MADCT1bN0M0 Ⅰa+C8/D852MADCT1aN0M0 Ⅰa−A9/B956FADCT1aN0M0 Ⅰa+C9/D960FADCT1aN0M0 Ⅰa−A10/B1057FADCT2N0M0 Ⅰb+C10/D1060FADCT2aN0M0 Ⅰb−A11/B1158MADCT1aN1M0 Ⅱa+C11/D1169MADCT1bN1M0 Ⅱa−A12/B1243MADCT2bN2M0 Ⅲa+C12/D1245MADCT1aN2M0 Ⅲa−[^1] Figure 1Pathological diagnosis of (**A**) lung cancer and (**B**) adjacent normal tissues (×400 times, hematoxylin and eosin staining).

Serological tests, DNA and total RNA extraction {#S0002-S2002}
-----------------------------------------------

We used Cpn IgA SeroFIA^TM^ and IgG SeroFIA^TM^ kits (Savyon, Israel) and the themicro-indirect immunofluorescence (MIF) method to detect serum Cpn IgG and IgA antibodies in patients with lung cancer. DNA was extracted using the Qiagen^®^ Genomic DNA Mini Kit, and total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacture's protocol. Purity and concentration were determined using the NanoDrop^®^ ND-2000 spectrophotometer. DNA and total RNA integrity were determined using 2% agarose gel electrophoresis.

DNA methylation and gene expression profiling {#S0002-S2003}
---------------------------------------------

After bisulfite conversion of DNA, the methylation profile of genomic DNA was assessed using the Infinium Human Methylation 450 Beadchip Kit (Illumina, San Diego, CA, USA), which can detect more than 450,000 methylation sites located within and outside CpG islands.[@CIT0010] Relative total RNA levels were also determined using the mRNA + lncRNA Human Gene Expression Microarray V4.0 (4×180 K format, CapitalBio Corp, Beijing, China), which is more specific for DNA-DNA hybridization and achieves low abundance of RNA amplification and detection efficiency. All samples were processed at the same time to avoid chip-to-chip variation. The quality of hybridization and overall chip performance were monitored using visual inspection of both the internal quality control checks and the raw scanned data.

Quantitative methylation analysis {#S0002-S2004}
---------------------------------

The Sequenom MassARRAY platform (CapitalBio Corp, Beijing, China) was used to perform quantitative methylation analysis of the target gene promoter.[@CIT0011] This system uses matrix-assisted laser desorption/ionization time-of-ﬂight (MALDI-TOF) mass spectrometry in combination with RNA base-speciﬁc cleavage (MassCLEAVE). PCR primers were designed with Methprimer (<http://epidesigner.com>). Each forward primer was tagged with a 10-mer to balance the PCR, and each reverse primer had an additional T7 promoter tag for in vitro transcription. The target regions were amplified using the primer pairs shown in [Table 2](#T0002){ref-type="table"}. The MethylTarget platform (GeneskyBio Corp, Shanghai, China) was also used to quantitatively analyze DNA methylation levels. The targeted DNA sequence was amplified by net-PCR and designed DNA fragments were sequenced using Illumina Hiseq 2000. PCR primers were designed with primer3 (<http://primer3.ut.ee/>).Table 2Primer design for validating the methylation level of gene fragmentsNamePrimer sequence^a^DirectionTarget lengthTarget position^b^Target CpGRIPK3L+GAGTTGATTGAATAATTTTTTTTATAGGF276−43 to +2326R+AACACCATCTCCACTCATAACCTAA[^2]

Accurate experimental methods and uniform judgment standards were adopted. The reagents were kept consistent during the experiment, and the consumables were autoclaved before each experiment. All samples were processed simultaneously to avoid heterogeneity between chips. Hybridization quality and overall chip performance were monitored using internal quality control checks and raw scan data.

Data processing and analysis {#S0002-S2005}
----------------------------

Infinium methylation data were processed using the GenomeStudio Methylation Module (v. 2011.1) in which methylation values (expressed as β-values, ranging from 0 to 1) and detection *P*-values were calculated. For quality control, methylation measures with a detection *P*-value \>0.05 were removed. The paired empirical Bayes moderated *t*-test in the limma package was used to obtain differential methylation positions (DMPs) (adjusted *P*-values (*q*-values) ≤0.05 and \| β-Difference \| ≥0.2) between cancer and adjacent normal tissues. The *q*-values were corrected using the Benjamini Hochberg method for multiple hypotheses, known as the false discovery rate method.[@CIT0012] Hierarchical cluster analysis of DMPs was carried out using complete linkage and Euclidean distance as a measure of similarity. Heatmaps were generated using the gplots package in R. We also used the hypergeometric test to investigate whether the CpG islets were enriched at a particular genomic location using 450 k as the background.

The 450 K methylation probes can be annotated into a gene's transcription start sites (TSS) 1500, TSS200, the 5ʹ untranslated region (UTR), the 1st exon, body, and the 3ʹUTR. Taking the TSS1500 region as an example, the TSS1500 region of one gene may contain multiple CpG sites. The mean value of the Beta values using multiple CpG sites on the gene TSS1500 region indicates the degree of methylation in this region. Therefore, we were interested in the impact of differential methylation regions (DMRs) on gene expression. The paired empirical Bayes moderated *t* test in the limma package was used to obtain DMRs (*q*-values ≤0.05) between cancerous and adjacent normal tissues.

Human Gene Expression raw signal data were processed using the Agilent Feature Extraction V12.0 and array normalization using the quantile method with limma packages. The genes detected in more than eight samples were used for differential expression analysis, and the paired empirical Bayes moderated *t* test in the limma package was used to identify differentially expressed genes (DEGs) (*q*-values ≤0.05 and \| Fold-Change (FC) \| \>2.0) between cancerous and adjacent normal tissues. The *q*-values were corrected using the Benjamini Hochberg method for multiple hypotheses. DEGs were further hierarchical clustered and filtered using Heatmaps and Volcano plots in R, respectively. Volcano plots were constructed using \| FC \| \> 2.0 and *q*-value ≤0.05 as cut-offs.

[Figure 2](#F0002){ref-type="fig"} shows a schematic diagram of the steps followed to identify the target genes. DMRs of the methylome and DEGs of the transcriptome were identified for Cpn positive lung cancer vs Cpn positive adjacent normal tissues ([Figure 2A](#F0002){ref-type="fig"} vs [B](#F0002){ref-type="fig"}) and Cpn negative lung cancer vs Cpn negative adjacent normal tissues ([Figure 2C](#F0002){ref-type="fig"} vs [D](#F0002){ref-type="fig"}). Integrative analysis using the Pearson's correlation was used to screen significantly different genes (DGs) with a negative correlation between DNA methylation of up-stream gene regions and expression levels (Pearson Correlation Coefficient \< −0.7 and *P*-value \<0.05). After removing the overlap of Cpn+ DGs and Cpn- DGs, the remaining set included Cpn-related lung cancer methylation genes (target genes). The target genes were entered into KOBAS (<http://kobas.cbi.pku.edu.cn/>) for Gene Ontology (GO) and pathway (KEGG, PID, BioCarta, Reactome, BioCyc and PANTHER) enrichment analysis with a *q*-value cutoff of 0.05. For all genes, gene sets enrichment analysis (GSEA) was evaluated according to MsigDB. In the validation analysis, the average methylation levels of each DNA fragment and CpG site were compared using the Wilcoxon Rank Sum test with a *P*-value cutoff of 0.05.Figure 2Schematic diagram of integrative methylome and transcriptome analyses.

Results {#S0003}
=======

Genome-wide DNA methylation distribution in Cpn-related NSCLC {#S0003-S2001}
-------------------------------------------------------------

We identified 5,309 DMPs including 3,619 hypermethylated and 1,690 hypomethylated probes in A vs B, and 6,213 DMPs including 4,032 hypermethylated and 2,181 hypomethylated probes in C vs D ([[Figure S1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)). Hierarchical clustering of DMPs showed separate clustering of non-small cell lung carcinoma (NSCLC) and adjacent normal tissues in both A vs B ([[Figure S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)) and C vs D ([[Figure S3]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)) indicating distinct epigenetic regulation.

Further we classified these DMPs based on their enrichment at CpG islands (CGIs), flanking CGIs (shores and shelves, 2--4 kb from CGIs), and open sea (non-related to CGIs). Our data showed that the majority of the hypermethylated probes (52%, 43%) were enriched in the CGIs ([[Figure S4A]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)--[[C]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)), whereas hypomethylated probes (68%, 70%) were mostly enriched in the open sea ([[Figure S4B]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)--[[D]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)). Hypermethylation in NSCLC was primarily enriched in the CpG-rich regions, while hypomethylation was primarily enriched in the open sea. When comparing the distribution of hypermethylated probes between A vs B ([[Figure S4A]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)) and C vs D ([[Figure S4C]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)), we found both were enriched in the CGIs. However, for all DMPs, we observed that A vs B was more enriched in the CGIs compared to C vs D ([[Table S1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217-TS1.xlsx)).

Gene expression profiles in Cpn-related NSCLC {#S0003-S2002}
---------------------------------------------

When subjected to principal component analysis (PCA) analysis, the contribution rate of the top 2 principal components was 51.90%. The gene expression profiles of the lung cancer and normal pairs in the two different Cpn status normal tissues (B, D) were relatively close, while that of Cpn positive and negative NSCLC cancer tissues (A, C) were markedly different, which tended to be disperse ([[Figures S5]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf) and [[S6]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)).

There was a total of 32,676 probe sets (transcripts) representing 20,753 genes on the Gene Chip. We observed significant differences in DEGs in A vs B and C vs D. Among these 2,765 genes 1,454 genes were up-regulated and 1,311 were down-regulated in A vs B, and 50 genes were up-regulated and 792 were down-regulated in C vs D ([[Figure S1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf) and [[Table S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217-TS2.xlsx)). Hierarchical clustering was applied to the expression profiles of the DEGs for Cpn positive NSCLC vs Cpn positive adjacent normal tissues (A vs B) and Cpn negative NSCLC vs Cpn negative adjacent normal tissues (C vs D). These data are represented by heatmaps ([[Figure S7]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf) for A vs B; [[Figure S8]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf) for C vs D) and volcano plots ([[Figure S9]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf) for A vs B and [[Figure S10]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf) for C vs D). The results indicate that DEGs could be used to distinguish cancerous tissues from normal tissues.

Transcriptional effects of aberrant DNA methylation {#S0003-S2003}
---------------------------------------------------

Changes of methylation in the upstream region of genes were inversely related to differential gene expression, so we screened a set of locus genes that were linked to the TSS1500, TSS200, 5ʹUTR and 1st Exon regions (all in the up-stream region) with an identified methylation site. For Cpn positive patients, 179 methylation probes were identified in A vs B; for Cpn negative patients, 174 methylation probes were identified in C vs D. For A vs B, we removed the data of the probes of C vs D. We found 124 methylation probes that were inversely related to gene expression, which indicated that we found 42 genes ([[Table S3]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217-TS3.xlsx)).

We also observed a negative correlation between gene upstream region methylation and gene expression ([Figure 3A](#F0003){ref-type="fig"} for A vs B; [Figure 3B](#F0003){ref-type="fig"} for C vs D). We used a combined analysis of the DEGs and DMRs. We found that gene expression profiles of 62 aberrantly methylated genes that existed in A vs B but not in C vs D were inversely correlated with promoter methylation ([Table 3](#T0003){ref-type="table"}).Table 3Combined analysis of differentially expressed genes and regional differential methylationGene nameBeta-Differencelog2FCPearson Correlation Coefficient*P*-valuePositionA2M0.1705−3.20614252−0.8374278550.0006761281stExonAGMAT−0.1591666671.35150382−0.8809353860.000153807TSS200AKAP20.18125−2.78702291−0.7698153540.003406655UTRANKRD34C0.099666667−1.43452865−0.6808037770.0148048411stExonANO9−0.04632.723041022−0.7892081190.002272594TSS200AURKB−0.0161.317301713−0.654413480.0209455045UTRB4GALT7−0.0299444441.68726944−0.7879449030.00233616TSS1500BTBD2−0.08252.170248508−0.8118620020.0013408021stExonCAV30.089−1.98277107−0.849825910.0004648485UTRCD5−0.1104166671.990345448−0.6695997490.0172221515UTRCD5−0.1104166671.990345448−0.6695997490.0172221511stExonCHRNE−0.1528333332.033405563−0.7959050150.001957367TSS200CRYAB0.038333333−1.92940006−0.6794177190.0150894411stExonCTDSPL0.034366667−1.50889147−0.7457380980.005360185TSS1500DCDC2B−0.0602083331.326446304−0.6439432930.023833279TSS1500DDR20.183666667−1.28964065−0.6999354490.011268077TSS200DNASE2−0.1311.63560986−0.7456901090.005364771TSS1500DRD50.069055556−1.31223918−0.8098594410.001408625TSS1500FAM83G−0.0367777781.510598922−0.7905543890.002206312TSS200FCGRT0.093520833−1.25654531−0.7476513430.005179749TSS1500FCGRT0.114266667−1.25654531−0.7517529260.004808407TSS200FXYD10.084296296−2.00910021−0.8519080830.000435101TSS1500FXYD10.1595−2.00910021−0.859421770.0003398411stExonFXYD60.088020833−1.52143406−0.8008467710.001747102TSS200FXYD60.062125−1.52143406−0.7492481540.005032697TSS1500G0S20.049625−2.55597963−0.8087663910.001446739TSS1500GPR55−0.1232777781.40233994−0.6091042860.035530718TSS1500GPX30.1235−1.70733757−0.7053062840.010399324TSS200HNF4A−0.08551.934479092−0.7269513010.007394059TSS1500IBSP−0.0532.712874451−0.6952830460.0120631955UTRIER20.028541667−1.96991612−0.6909619450.01283825TSS1500IKBKE−0.0623888892.697424492−0.753151010.0046865475UTRINMT0.120666667−1.47252997−0.7797603550.0027815561stExonITIH2−0.1941666671.704574286−0.7172543190.0086462421stExonLRRC56−0.0575333332.011179421−0.7250651880.0076262245UTRLRRC56−0.0183333332.011179421−0.6175850180.0323700251stExonLTA−0.0939166671.352498731−0.6992206180.01138764TSS1500MACROD1−0.0625833331.503512762−0.7623755780.003940007TSS1500MAPRE3−0.0301538462.418662642−0.7762388530.0029919385UTRMT1A0.119666667−1.77417907−0.6847097960.01402415UTRMYO1C0.051466667−1.09237987−0.609951490.035205449TSS200MYO1C0.050545455−1.09237987−0.6456020980.023357564TSS1500NEFL0.059666667−1.64334004−0.6997735080.011295081TSS1500NFKBIE−0.0992222221.249279877−0.7214589570.00808527TSS1500OLFML10.11−1.65131157−0.8858764030.000125511TSS200OLFML10.202333333−1.65131157−0.8724798410.0002135685UTROLFML10.202333333−1.65131157−0.8724798410.0002135681stExonOPTC−0.0223751.490102398−0.7131283720.009224489TSS1500PCDHB40.096366667−1.10626023−0.7400564920.00592402TSS200PCDHB40.086277778−1.10626023−0.6800269540.014963855TSS1500PMP220.05352381−2.19707598−0.6158475860.033000441TSS1500PYDC1−0.0849166671.458731243−0.6487359750.022477711TSS1500RCC1−0.1200666672.163364397−0.7375760470.006183702TSS1500RGS14−0.1591111112.991134915−0.7264186510.00745908TSS200RGS14−0.0971111112.991134915−0.6818701320.014588595TSS1500RHOV−0.0773333331.409150164−0.6510328370.02184835TSS1500RIPK3−0.1021666672.274888316−0.7301160060.007016463TSS200RIPK3−0.1220416672.274888316−0.7030651980.010755538TSS1500RIPK3−0.0817777782.274888316−0.6787473470.0152285255UTRRIPK3−0.0817777782.274888316−0.6787473470.0152285251stExonRPAP20.016916667−1.03892684−0.7650395520.0037422395UTRRPAP20.016916667−1.03892684−0.7650395520.0037422391stExonSALL30.167583333−2.25513937−0.6623552230.018931937TSS1500SALL30.171333333−2.25513937−0.8888225650.0001106911stExonSCRN2−0.0336666671.114621646−0.7837503220.00255702TSS1500SEPT100.022785714−1.62973024−0.6361392960.026166172TSS200SEPT100.155333333−1.62973024−0.7682075490.0035169635UTRSEPT100.155333333−1.62973024−0.7682075490.0035169631stExonSLC35B2−0.0440555561.779433339−0.6772359730.015545557TSS1500SLIT20.049−1.8350073−0.873490990.0002055985UTRSLIT20.049−1.8350073−0.873490990.0002055981stExonSOX50.042−1.73714341−0.7641611820.0038065951stExonSPINT1−0.0461.777841017−0.8003785940.0017662441stExonSPON10.087027778−1.88844713−0.7362700520.006323822TSS200STOML3−0.0420416671.232677275−0.7856195880.002456714TSS1500STX120.019083333−1.28519266−0.7752148950.003055325TSS200SYTL3−0.1038333331.912604554−0.6079555140.0359751921stExonTNF−0.0963888891.311252028−0.7125400540.009309233TSS1500TRIM31−0.22451.268419408−0.7422545380.005700841TSS200TRIM31−0.1624166671.268419408−0.7421452740.0057117845UTRZNF5780.105916667−1.34457748−0.6097991680.0352637735UTR Figure 3The inverse relationship between gene upstream region methylation and gene expression. (**A**) Heatmaps of negative correlation between DMRs and DEGs for Cpn positive NSCLC vs Cpn positive adjacent normal tissues (A vs B), and (**B**) Cpn negative NSCLC vs Cpn negative adjacent normal tissues (C vs D). In DNA methylation, "Red" indicates relative hypermethylation, and "Blue" indicates relative hypomethylation. In gene expression, "Red" indicates up-regulated genes, and "Blue" indicates down-regulated genes.

Cpn-related lung cancer genes (target genes) and potential biological function analysis {#S0003-S2004}
---------------------------------------------------------------------------------------

In total, 62 target genes were submitted for GO and pathway (KEGG, PID, BioCarta, Reactome, BioCyc and PANTHER) enrichment analysis. For biological processes, positive regulation of chronic inflammatory response to antigenic stimulus (GO: 0002876) was the most represented GO term, followed by negative regulation of growth (GO: 0045926) and regulation of chronic inflammatory response to antigenic stimulus (GO: 0002874). For cellular components, the major represented categories were membrane raft (GO: 0045121). Genes involved in important molecular functions were also identified, such as nuclear factor-kappa B-inducing kinase activity (GO: 0004704) ([Figure 4](#F0004){ref-type="fig"}). Using the KEGG pathway database, we found that tumor necrosis factor (TNF) and receptor-interacting serine/threonine-protein kinase 3 (RIPK3) overexpression by hypomethylation of the promoter region may activate the TNF signaling pathway (hsa04668, [[Figure S11]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)). RIPK3 and inhibitor of nuclear factor-kappa B kinase subunit epsilon (IKBKE) may play a role in responding to bacterial invasion in the cytosolic DNA-sensing pathway (hsa04623, [[Figure S12]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)). Furthermore, we also found that the first ranked pathway in the Reactome database was Methylation of MeSeH for excretion (R-HSA-2408552). In PANRHER, we found a number of target genes that were involved in the adrenaline and noradrenaline biosynthesis pathway (P00001) and Toll receptor signaling pathway (P00054). Details are shown in [Figure 5](#F0005){ref-type="fig"}. We also conduced GSEA for all 20,198 genes. The Heat map and gene list correlation profile in the dataset for the comparison of A vs B ([[Figure S13]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)) and C vs D ([[Figure S14]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=186217.pdf)) are shown. Our data indicate that DNA methylation can affect the binding of transcription factors to genes.Figure 4Cpn-related lung cancer genes (target genes) and potential biological function analysis. Gene ontology for the top 30 biological processes, cellular components, and molecular functions annotation.Figure 5KEGG, PID, BioCarta, Reactome, BioCyc and PANTHER pathway enrichment analysis for all 62 target genes.

Quantitative methylation analysis and validation {#S0003-S2005}
------------------------------------------------

Among the 62 target genes that were the most representative aberrantly methylated genes of Cpn-associated lung cancer, *RIPK3* was verified using 24 microarray samples as the most methylated in all promoter regions (TSS1500, TSS200, 5ʹUTR and 1stExon regions) and was enriched in innate immune responses for foreign DNA from invading microbes in pathway analysis. Furthermore, methylation levels were quantified against the DMRs in the promoter regions of *RIPK3*. The Wilcoxon Rank Sum test showed that, in the Cpn positive group, the average methylation level of *RIPK3* in lung cancer samples was significantly lower than that in the para-cancer control samples (7.25% vs 11.67%, *P*=0.005), but the difference was not significant in the Cpn negative group (8.96% vs 12.54%, *P*=0.093). The lowest methylation level of *RIPK3* was found in Cpn-positive lung cancer samples, and in the 2nd, 4th, and 5th CpG sites there was a significant difference in methylation levels between lung cancer and para-cancer control samples in the Cpn-positive group, but not in the Cpn negative group ([Figure 6](#F0005){ref-type="fig"}). For the differentially expressed methylation sites in the *RIPK3* promoter regions screened using chip and first validation, DNA methylation levels were verified on samples numbered ABDC 7--12. Only the 5th CpG site of *RIPK3* was statistically significant in A vs B (*P*=0.041), and not in C vs D (*P*=0.310).Figure 6Methylation levels of the CpG sites in the *RIPK3* promoter. (**A**) Schematic diagram of the *RPIK3* promoter. The sequence represents a 276-base pair fragment (−43 bp to +232 bp) in *RPIK3*. The start of the 1st exon was considered as +1 of the sequence. Numbers 1--6 refer to locations of the CpG sites within the *RIPK3* elements tested, and underlining shows the number of multiple CpG sites that were tested simultaneously. (**B**) Comparison of the methylation levels of CpG sites in *RIPK3* promoter regions. Data are expressed as Median (P~25~, P~75~). \* Wilcoxon Rank Sum test was performed: \**P*\<0.05(relative to the respective control: **B** or **D**). n~case~ =6, n~control~ =6.

Discussion {#S0004}
==========

Lung cancer is the most prevalent and deadly cancer in the world. In addition to an imbalance in proto- and anti-oncogenes, aberrant promoter hypermethylation is now recognized as an essential component in lung cancer progression.[@CIT0013] Infection has been found to be closely related to abnormal DNA methylation and can further induced cancer.[@CIT0014],[@CIT0015] The development of chip techniques has led to novel approaches to lung cancer classification and diagnosis. We investigated the genome-wide DNA methylation and gene expression profiling of 12 NSCLC (6 Cpn positive and 6 Cpn negative) and 12 paired adjacent lung tissues. The target genes of Cpn infection-associated lung cancer were enriched in several representative pathways, including positive regulation of chronic inflammatory response to antigenic stimulus (GO: 0002876), negative regulation of growth (GO: 0045926), regulation of chronic inflammatory response to antigenic stimulus (GO: 0002874), membrane raft (GO: 0045121) and nuclear factor-kappa B-inducing kinase activity (GO: 0004704). *RIPK3* and *IKBKE* were enriched in the TNF signaling pathway (hsa04668) and the cytosolic DNA-sensing pathway (hsa04623). Chip and validation screening demonstrated that the abnormal methylation sites in the promoter regions of *RIPK3* were associated with Cpn-related lung cancer.

A recent study[@CIT0016] on Chlamydia trachomatis (Ct) and ovarian cancer suggested that Chlamydia infection promotes host DNA damage, causing malignant cell proliferation, which permanently affects the host at the genomic and epigenetic levels, particularly through altering host chromatin structure by DNA methylation and post-translational histone modifications. Cpn can induce histone H3 and H4 modifications, which have a major effect on cytokine production.[@CIT0016] Ct infection was associated with increased expression of two mesenchymal cell markers: fibronectin and α-smooth muscle actin (α-SMA). The DNA methylation status of selected regions of E-cadherin, fibronectin, and α-SMA genes revealed that Ct infection was accompanied by changes in DNA methylation of the E-cadherin promoter.[@CIT0017] A whole genome sequencing study[@CIT0018] of Cpn showed that there are many enzymes involved in the synthesis and metabolism of aromatic compounds, such as synthetase, hydroxylase, decarboxylase, and methylase. However, there have been no Cpn-related methylation studies. We speculated that Cpn may lead to abnormal methylation of human genomic DNA, resulting in abnormal activation of oncogenes and transcriptional silencing of tumor suppressor genes, causing disordered cell growth and differentiation.

It is well known that DNA methylation of the promoter region strongly correlates with transcriptional repression, and that DNA methylation downstream of the TSS, in particular of the 1st exon, is critical for transcriptional silencing, independent of the cell type. In the current study, we found an inverse relationship between Cpn-related DMPs and DEGs. We identified Cpn-related DMRs for 62 significant target genes. These genes were enriched in several representative pathways, including positive regulation of chronic inflammatory response to antigenic stimulus, regulation of chronic inflammatory response to antigenic stimulus, and nuclear factor-kappa B-inducing kinase activity, among others. The biological function of most of these genes was related to chronic infection, which indicates that Cpn might be involved in the progression of lung cancer through DNA methylation changes.

Validation experiments showed that *RIPK3* was enriched in the TNF signaling pathway and cytosolic DNA-sensing pathway, and was hypomethylated in the corresponding promoter regions. We also found that *RIPK3* was a unique aberrant methylated gene in Cpn-positive lung cancer tissues. There was an inverse relationship between methylation of the promoter region and transcriptional activity.[@CIT0019],[@CIT0020] Hypomethylation of CpG islands in the promoter can result in gene overexpression. The start of the 1st exon was considered as +1 of the sequence, and *RIPK3* was located in the promoter region from −43 bp to +232 bp (276 bp total). A previous study showed that reduced methylation of the *RIPK3* promoter triggered expression of *RIPK3* in RIPK3-null cancer cells[@CIT0021] and treatment with hypomethylating agents restored *RIPK3* expression.[@CIT0022] *RIPK3* was a component of the tumor necrosis factor receptor-I signaling complex that activated NF-κB transcription factors[@CIT0023],[@CIT0024] and further initiated cell proliferation, apoptosis resistance, and malignant transformation. However, recent studies showed that RIPK3, RIPK1, and mixed-lineage kinase domain-like protein (MLKL) formed a multi-protein complex, called a necrotic body,[@CIT0023],[@CIT0025],[@CIT0026] which regulated programmed cell necrosis.[@CIT0027] This was considered a new type of necrosis that is dependent on genetic programming and regulation.[@CIT0028] Programmed necrosis does not depend on the traditional caspase apoptotic pathway and has been defined as RIPK3-dependent necrotizing cell death.[@CIT0029] In contrast, programmed necrosis provided the host with an autonomous defense, and cell rupture caused by programmed necrosis induced inflammation by releasing the damage-related molecules. Increasing evidence suggests that programmed necrosis is related to clinical diseases.[@CIT0029] Necrosis played not only a protective role but also a detrimental role in the pathogenesis of pulmonary diseases, such as chronic obstructive pulmonary disease and lung cancer,[@CIT0030] and is therefore an important potential therapeutic target.[@CIT0028] Contrary to the result of our study, recent data suggest that *RIPK3* expression is often silenced in cancer cells due to genomic methylation near its transcriptional start site.[@CIT0022],[@CIT0031] Fukasawa et al[@CIT0032] compared the methylation levels of 288 cancer-associated gene promoters between lung cancer cells and normal lung cells. In the majority of lung cancer cell lines, *RIPK3* was hypermethylated and down-regulated. The methylated frequency of *RIPK3* was highest in small cell carcinoma. Outcome differences might be due to the different pathological types of lung cancer studied. It would be interesting to discuss the role of *RIPK3* in development of lung cancer and its association with methylation by histological subtype.

In the present study, we also identified other Cpn-related target genes. Neurofilament (NF) is an intermediate filament found in the cytoplasm of central and peripheral nervous system neurons. It is a type IV intermediate filament heterodimer composed of light (NEFL), middle, and heavy chains,[@CIT0033] which provide structural support of axons and adjusts axon diameter to control the rate of electrical signals traveling along the axon.[@CIT0034] A recent study reported that abnormal methylation and expression of NF genes were detected in esophageal squamous cell carcinoma,[@CIT0035] breast cancer,[@CIT0036] renal cell carcinoma,[@CIT0037] hepatocellular carcinoma,[@CIT0038] and Ewing's sarcoma.[@CIT0039] We found that hypermethylation of NEFL TSS1500 regions in Cpn-positive lung cancer tissues inhibited the expression of NEFL, which might contribute to the development of Cpn-associated lung cancer. Another study showed that NEFL expression regulated by promoter hypomethylation, which inhibits the NF-κB pathway, was associated with suppressed invasion and migration of NSCLC cell lines and patients.[@CIT0040]

More recently dopamine and its receptors have been indicated as regulatory factors for immune cells and malignant cell proliferation.[@CIT0041] The bioavailability of dopamine is regulated by dopamine receptors (DRs),[@CIT0042] which are G protein-coupled receptors. DRs are divided into different classes - D1 (D1 and D5) and D2 (D2, D3, and D4) -- and are expressed in alveolar epithelial cells. The expression of DRs might be affected by corresponding DNA methylation levels. Liao et al[@CIT0043] used methylation-sensitive representational difference analysis to screen gastric cancer and normal gastric mucosa, and found the promoter and exon regions of DRD5 were differentially methylated DNA sequences. DRD5 promoted adenylate cyclase to synthesize cAMP by activating the Gαs/olf family of G proteins.[@CIT0044] cAMP is an important second messenger in many biological processes and cAMP pathway dysregulation is related to the development of cancer. Our results showed that, in Cpn-related lung cancer, down-regulated DRD5 expression mediated by changes in corresponding promoter methylation status inhibited adenylate cyclase, thereby decreasing intracellular cAMP accumulation. This promoted the mitotic proliferation of cells, which may ultimately lead to development of lung cancer. The function of DRD5 in lung cancer requires further investigation.

There is currently no gold standard for detecting Cpn antigen levels, and the detection rate of existing methods is relatively low, increasing the difficulty of determining if patients have an active infection. Thus, in this study, serum Cpn IgG and IgA levels were detected using MIF, which is the standard for serologic detection of Chlamydia infection. Limited by the design of our case-control study, we only explored the relationship between chlamydia and lung cancer. Thus, Cpn infection may be involved in lung cancer development, and well-designed cohort studies and randomized controlled trials are needed to minimize the effect of disease on antibody titers, reduce selection bias, and better adjust for potential confounders.

This study explored the epigenetic mechanism of Cpn infection in lung cancer. Our integrative methylome and transcriptome analyses revealed that Cpn infection contributed to methylation-mediated changes in *RIPK3*. Activation of the NF-κB pathway, TNF signaling pathway, and cytosolic DNA-sensing pathway might be involved in the development and progression of lung cancer. Case-control studies have inherent limitations, such as selection bias and recall bias, that are difficult to avoid, and thus the same methylation sites may have distinctly different regulatory roles depending on factors such as race, tissue sample, and time of expression. New study designs and sample sizes may provide better insight into the association between Cpn infection, gene methylation, and lung cancer. Therefore, the results of this study need to be further validated in a multi-center, rigorously designed large sample study, and the specific mechanism needs to be further explored using relevant functional studies.
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Abbreviation list {#S0005}
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Cpn, Chlamydia pneumonia; GO, gene ontology; MIF, micro-indirect immunofluorescence; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-ﬂight; MassCLEAVE, mass spectrometry in combination with RNA base-speciﬁc cleavage; DMPs, differentially methylated positions; DMRs, differentially methylated regions; DEGs, differentially expressed genes; DGs, differentially genes; FC, Fold-Change; TSS, transcription start sites; GSEA, gene sets enrichment analysis;NSCLC, non-small cell lung cancer; CGIs, CpG islands; PCA, principal component analysis; TGFBR, transforming growth factor beta receptor; IKBKE, inhibitor of nuclear factor-kappa B kinase subunit epsilon; RIPK3, receptor-interacting serine/threonine-protein kinase 3; DRD5, dopamine receptor D5; NEFM, neurofilament medium; NEFL, neurofilament light; DR, dopamine receptors; MS-RDA, methylation-sensitive representational difference analysis; cAMP, cyclic adenosine monophosphate.
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[^1]: **Abbreviations:** No, No. of lung cancer tissue/No. of adjacent normal tissue; F, Female; M, Male; ADC, Adenocarcinoma; SCC, Squamous cell carcinoma.

[^2]: **Notes:** ^a^L = aggaagagag, R = cagtaatacgactcactatagggagaaggct. ^b^The position of the transcription start site in the sequence is considered to be +1.
